Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) – Stock analysts at Jefferies Group increased their Q2 2018 EPS estimates for Aevi Genomic Medicine in a research report issued on Wednesday, May 16th. Jefferies Group analyst M. Andrews now anticipates that the biotechnology company will post earnings of ($0.15) per share for the quarter, up from their prior estimate of ($0.17). Jefferies Group also issued estimates for Aevi Genomic Medicine’s Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.15) EPS, FY2018 earnings at ($0.61) EPS, FY2019 earnings at ($1.27) EPS, FY2020 earnings at ($1.60) EPS, FY2021 earnings at ($1.36) EPS and FY2022 earnings at ($1.40) EPS.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01).
Aevi Genomic Medicine opened at $1.62 on Friday, Marketbeat Ratings reports. The firm has a market capitalization of $89.60 million, a price-to-earnings ratio of -1.95 and a beta of 1.10. Aevi Genomic Medicine has a 52 week low of $1.50 and a 52 week high of $1.53.
Large investors have recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in shares of Aevi Genomic Medicine by 515.8% in the fourth quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 78,400 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Aevi Genomic Medicine by 433.7% in the third quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 106,178 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Aevi Genomic Medicine by 4,715.1% in the first quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 99,018 shares in the last quarter. Institutional investors and hedge funds own 20.41% of the company’s stock.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.